



Working together to improve pain policy

Dott. Alberto Grua

May 24 – SIP 2016

Grünenthal

The challenge




- **One in five** adults suffers from chronic pain. (46,364 people surveyed across 16 Europe countries)
- **19%** (i.e. 75m in Europe) suffer Chronic pain (pain for at least 6 months duration, several times a week, Pain intensity >5/10)
- On average, patients live with chronic pain for **7 years** (20% >20 years)
- **One third** reported that their pain was so severe they could not tolerate it any more
- **One in five** reports losing a job or have been diagnosed with depression as a result of their pain
- **36%** have inadequate pain control from medication

Pain constitutes a major cause of long-term sick leave and forced early retirement, placing a great financial burden on both individuals and healthcare systems.

Despite extensive research programs by pharmaceutical companies and academia, there **remains a need for treatments that are more effective and with fewer side-effects.**

At SIP 2011 and SIP 2012 IMI Principal Scientific Manager Elisabetta Vaudano presented the IMI EuroPain initiative

EuroPain The Innovative Medicines Innovative
Joining Forces in the Healthcare Sector



The diagram illustrates the IMI EuroPain initiative. It features a large green circle containing the IMI logo at the top. Below the logo, the text "2 Billion Euro" is displayed. Underneath, two smaller circles represent the funding sources: a blue circle on the left labeled "1 Billion €" with the European Union flag and the word "Public" below it; and an orange circle on the right labeled "1 Billion €" with the efpia logo and the word "Private" below it. The word "Partnership" is centered at the bottom of the large green circle.


imi

2 Billion Euro


1 Billion €
Public

1 Billion €
efpia
Private

Partnership

imi **efpia** 





The Innovative Medicines Initiative is the largest public-private partnership for health research worldwide

work in progress: The IMI Pain Group in 2016 Several Projects in preparation

Members: **Grünenthal, Esteve, Bayer, Lilly, JnJ , Novartis.**

Specific projects are in preparation which will facilitate an **optimized management of pain patients.**

These projects cover the spectrum from **early research** to **clinical practice** and focus on **acute** or **chronic pain** incl. **pelvic and neuropathic** pain, reflecting the **diversity of pain.**

Planned to start in **2016:**


- Pathological neuron-glia cross-talk involved in neuropathic pain.

Planned to start in **2017:**

- Use of Patient Reported Outcome Measures (PROMs) for patient-health care professional contacts in acute and chronic pain management.
- Improving translation in chronic pelvic pain.
- Translatability of functional biomarkers in chronic pain pathways.

SIP 2016

- over 210 registered participants
- representing 28 nationalities
- Representing over 135 organisations
- over 300 organisations have endorsed the SIP symposia
- over 160 organisations endorsed SIP 2016
- high patronage of the Italian Ministry of Health
- over 20 MEP's supporting (16 actively involved in the program)
- 82 persons on the program (all of them very well respected in their fields).



- **To ensure access to adequate pain treatment for all citizens**
- **To unite all organisations and societies advocating better pain care to jointly address, define and foster pain policies**



in order to address to
societal impact of pain
we will all need to work
together



